OCEANS enables rapid, accurate, and affordable detection of somatic mutations as low as 0.05% VAF. This novel research will facilitate the development of same-day, low-cost oncology panels for time-sensitive therapy selection and recurrence monitoring.
NuProbe will integrate QASeq and BDA technologies with Bionano’s Saphyr system for research and product development in the fields of reproductive health and oncology liquid biopsies.
NuProbe published research on DNA microsatellites in Nucleic Acids Research and released VarTrace® MSI qPCR research use only assay.
The findings, published in Nature Communications, are the latest research leveraging machine learning to improving the efficiency and accuracy of genomics. The study was co-authored by researchers from NuProbe USA, Rice University, and Microsoft Research UK.
Research published in Nature Biomedical Engineering demonstrates NuProbe’s technology can enable detecting SNVs in DNA with a VAF of ≤0.02% using a sequencing depth of only 250x.
The VarMap Pan-Cancer NGS Panel uses the quantitative blocker displacement amplification technology to enrich, detect, and quantitate over 6500 mutations and indels in 61 clinically relevant genes. The panel can be used on cfDNA samples to detect mutations down to 0.1% variant allele frequency (VAF) using only 1 million NGS reads. The panel can also be applied to FFPE tumor samples or other cellular samples for minimum residual disease (MRD) detection, detecting mutations down to 0.01% VAF.
The lead investors for this financing round are BioTrack Capital and Yonghua Capital. The proceeds will be used to expand the commercial team in both the US and China, develop new NGS products, and file for regulatory approval in China for NuProbe’s clinical products.
NuProbe launches the Augury™ platform for automated design of customized liquid biopsy NGS panels. Based on proprietary sequence-design algorithms, Augury™ will procedurally generate NGS panels for cell-free DNA (cfDNA) analysis, covering the entire coding regions of between 1 and 30 genes of interest.
NuProbe and Weigao Group will apply NuProbe’s proprietary Blocker Displacement Amplification (BDA) technology to developing a liquid biopsy NGS panel for non-small cell lung cancer (NSCLC). The product will be compatible with the desktop NGS instruments, and the companies plan to later apply for in vitro diagnostic (IVD) registration with NMPA, China’s equivalent of FDA.
The first, Non-Extensible Oligonucleotides (NEO), will allow NuProbe to provide much more rapid development of customized NGS panels, with turnaround time of less than 4 weeks. The second, Linear DNA Assembly (LDA) technology, improves the effective throughput of nanopore sequencing by up to 10-fold for short DNA, such as DNA extracted from FFPE tumor tissues and cell-free DNA from peripheral blood. Concurrently, NuProbe announces the launch of its new VarMap™ Nanopore product line.